Davies, G. L. S. (2003) Cyclooxygenase-2 and chemoprevention of breast cancer. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 86 (3-5). pp. 495-499. ISSN 0960-0760

Full text not available from this repository.

Abstract

Cyclooxygenase-2 and chemoprevention of breast cancer. This article discusses the role of cycclooxygenase-2 (COX-2) in the aetiology and progression of breast cancer. Renewed interest in chemoprevention using non-steroidal anti inflammatory drugs (NSAIDS) has come from observations that regular NSAID use is associated with a reduced incidence of some cancers including that of the breast. There is an increasing body of evidence supporting a role for COX-2 in breast cancer development and progression via effects on angiogenesis and apoptosis as well as via effects on intratumoural aromatase. New selective inhibitors of COX-2 are currently licensed for use in the treatment of arthritis and more recently in the chemoprevention of familial adenomatous polyposis (FAP). Large clinical chemoprevention studies with COX-2 inhibitors are already underway in colorectal cancer. Their role in breast cancer prevention and treatment has yet to be fully characterised, but merits further investigation. (C) 2003 Published by Elsevier Ltd.

Item Type:	Article
All Authors:	Davies, G. L. S.
Uncontrolled Keywords:	cyclooxygenase-2; breast cancer; angiogenesis; aromatase; chemoprevention Nonsteroidal antiinflammatory drugs; gene-expression; adipose- tissue; aromatase gene; tumor; celecoxib; risk; mice; inhibition; activation
Research teams:	Clinical Units > Other Royal Marsden Services/Clinical Units
Depositing User:	EPrints Services
Date Deposited:	10 Aug 2007 20:42
Last Modified:	09 Apr 2015 10:43
URI:	http://publications.icr.ac.uk/id/eprint/1338

Actions (login required)

View Item